Company intelligence / Profile preview

Diamond Therapeutics

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Diamond Therapeutics is developing sub-perceptual, low-dose psilocybin-based small-molecule therapies for neuropsychiatric conditions; as of 2023–2024 it has advanced psilocybin into early clinical studies in mental health indications, but no pivotal efficacy data are yet published.[9][3]

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Diamond Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diamond Therapeutics.

Explore the full profile